Monotherapy with atazanavir as a simplificati strategy: Results from an observational study

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 3, 2012, Pages

  Cossarini, Francesca ^a   Salpietro, Stefania ^a   Galli, Laura ^a   Gianotti, Nicola ^a   Nozza, Silvia ^a   Spagnuolo, Vincenzo ^a   Hasson, Hamid ^a   Bossolasco, Simona ^a   Lazzarin, Adriano ^a   Tambussi, Giuseppe ^a   Castagna, Antonella ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; BILIRUBIN; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; FOSAMPRENAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OLIGOPEPTIDE; PYRIDINE DERIVATIVE; VIRUS RNA;

ADULT; BILIRUBIN BLOOD LEVEL; DRUG POTENCY; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG TOXICITY; DYSLIPIDEMIA; FEMALE; HEART TOXICITU; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY TOXIC; LETTER; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; TREATMENT FAILURE; BLOOD; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; IMMUNOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT FAILURE;

EID: 84864302510     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318258bf3c     Document Type: Letter

References (11)

1. Hall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIVinfected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773-780.
2. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis. 2002;34:838-846.
3. Koczor CA, Lewis W. Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Expert Opin Drug Metab Toxicol. 2010;6:1493-1504.
4. Cherry CL, McArthur JC, Hoy JF, et al. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol. 2003;26:195-207.
5. Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavirritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008;22:F1-F9.
6. Arribas JR, Delgado R, Arranz A, et al. Lopinavir-ritonavir monotherapy versus lopinavirritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr. 2009;51:147-152.
7. Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010;24:2365-2374.
8. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA. 2006;296:806-814.
9. Karlstrom O, Josephson F, Sonnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr. 2007;44:417-422.
10. Vernazza P, Daneel S, Schiffer V, et al. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS. 2007;21: 1309-1315.
11. Pineda JA, Palacios R, Rivero A, et al. Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir. J Antimicrob Chemother. 2006;57:1016-1017.